Cytosorbents

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytosorbents and other ETFs, options, and stocks.

About CTSO

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. 

CEO
Phillip P. Chan
CEOPhillip P. Chan
Employees
149
Employees149
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1997
Founded1997
Employees
149
Employees149

CTSO Key Statistics

Market cap
37.67M
Market cap37.67M
Price-Earnings ratio
-4.45
Price-Earnings ratio-4.45
Dividend yield
Dividend yield
Average volume
128.29K
Average volume128.29K
High today
$0.62
High today$0.62
Low today
$0.56
Low today$0.56
Open price
$0.62
Open price$0.62
Volume
158.34K
Volume158.34K
52 Week high
$1.39
52 Week high$1.39
52 Week low
$0.4992
52 Week low$0.4992

Stock Snapshot

As of today, Cytosorbents(CTSO) shares are valued at $0.59. The company's market cap stands at 37.67M, with a P/E ratio of -4.45.

During the trading session on 2026-03-28, Cytosorbents(CTSO) shares reached a daily high of $0.62 and a low of $0.56. At a current price of $0.59, the stock is +5.9% higher than the low and still -4.4% under the high.

Trading activity shows a volume of 158.34K, compared to an average daily volume of 128.29K.

Over the past 52 weeks, Cytosorbents(CTSO) stock has traded between a high of $1.39 and a low of $0.50.

Over the past 52 weeks, Cytosorbents(CTSO) stock has traded between a high of $1.39 and a low of $0.50.

CTSO News

TipRanks 1d
Cytosorbents’ Earnings Call Balances Progress and Risk

Cytosorbents Corp ((CTSO)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 30% Off TipRanks Premium Unlock hedge fund-level da...

The Motley Fool 2d
Cytosorbents Q4 2025 Earnings Transcript

Image source: The Motley Fool. Wednesday, March 25, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Phillip Chan Chief Financial Officer — Pet...

Cytosorbents Q4 2025 Earnings Transcript
TipRanks 2d
CytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory Risks

H.C. Wainwright analyst Sean Lee CFA maintained a Hold rating on Cytosorbents today and set a price target of $0.75. Sean Lee CFA has given his Hold rating due...

More CTSO News

TipRanks 2d
CytoSorbents Narrows Losses Amid Strategic Shift and Growth

Cytosorbents ( (CTSO) ) has issued an announcement. On March 25, 2026, CytoSorbents reported that revenue for the year ended December 31, 2025 rose 4% to $37.1...

TipRanks 2d
CytoSorbents reports Q4 adjusted EPS (7c) vs. (3c) last year

Reports Q4 revenue $9.23M vs. $9.15M last year. “2025 was a transitional year for our business as we made good progress in four key objectives,” stated Dr. Phil...

People also own

Based on the portfolios of people who own CTSO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.